Two distal enhancers that specify apolipoprotein (apo) E gene expression in isolated macrophages and adipose tissue were identified in transgenic mice that were generated with constructs of the human apoE/C-I/ C-I/C-IV/C-II gene cluster. One of these enhancers, multienhancer 1, consists of a 620-nucleotide sequence located 3.3 kilobases (kb) downstream of the apoE gene. The second enhancer, multienhancer 2, is a 619-nucleotide sequence located 15.9 kb downstream of the apoE gene and 5.9 kb downstream of the apoC-I gene. The two enhancers are 95% identical in sequence, and they are likely to have arisen as a consequence of the gene duplication event that yielded the apoC-I gene and the apoC-I pseudogene. Both enhancer sequences appear to have equivalent activity in directing apoE gene expression in peritoneal macrophages and in adipocytes, suggesting that their activity in specific cell types may be determined by common regulatory elements.
Apolipoprotein (apo)
1 E is a M r ϭ 35,000 protein with multiple functions in lipid metabolism (1) . It is a component of large remnant lipoproteins and large high density lipoproteins in plasma. ApoE has a key role in the metabolism of plasma lipoproteins by serving as a ligand for the low density lipoprotein (LDL) receptor family and binding to heparan sulfate proteoglycans. These functions of apoE mediate the clearance of remnant lipoproteins and apoE-rich large high density lipoproteins from plasma, resulting in the redistribution of cholesterol and triglycerides between peripheral tissues and the liver. Three common variants, E2, E3, and E4 (2, 3) , that affect the properties of human apoE have been identified as a consequence of having either arginine or cysteine at residues 112 and 158 (4 -6) . The most abundant variant in the normolipidemic human population is E3 (7) . The E2 variant is defective in binding to receptors, and homozygosity for apoE2 is sometimes associated with type III hyperlipidemia and premature atherosclerosis (8) . The E4 variant increases the formation of amyloid plaques and neurofibrillary tangles that are characteristic of Alzheimer's disease, making apoE4 a significant risk factor for this neurodegenerative disorder (9 -11) . ApoE4 is also associated with a moderate elevation in plasma cholesterol and an increased risk for coronary artery disease (5, 7) .
Macrophages have long been recognized as a source of apoE (12) . ApoE is a marker for the developmental state of macrophages; the culture of mouse bone marrow cells in vitro shows that mature macrophages, but not their monocytic precursors, synthesize apoE (13) . Thioglycollate-elicited peritoneal macrophages synthesize and secrete apoE. Bacterial endotoxin and other inflammatory agents decrease its production (14) . Resident macrophages in a variety of tissues, including liver Kupffer cells (15) and brain microglia (16, 17) , either synthesize or can be induced to synthesize apoE. Dexamethasone, a synthetic glucocorticoid, increases apoE mRNA levels in mature macrophages up to 6-fold over basal levels (18) . The uptake of acetylated LDL or cholesterol ester-rich ␤-migrating very low density lipoproteins into peritoneal macrophages stimulates apoE synthesis and secretion by 3-8-fold (12) . The response of macrophages to cholesterol is due to increased apoE gene transcription and higher apoE mRNA levels (19) . Lipidloaded, macrophage-derived foam cells in aortic atherosclerotic lesions of cholesterol-fed rabbits synthesize and secrete apoE and appear to be the major source of apoE in the atherosclerotic arterial wall (20, 21) . The transfer of apoE-secreting macrophages into apoE-deficient mice by either bone marrow transplantation (22, 23) or cross-breeding with transgenic lines (24) reduces the incidence of vascular lesions, and the animals become resistant to dietary cholesterol-induced atherosclerosis.
ApoE synthesis has been reported in both human and mouse adipose tissue (25) . ApoE mRNA has also been detected in confluent cultured mouse fibroblasts that have been induced to become adipocytes by dexamethasone and insulin. Undifferentiated fibroblasts do not contain apoE mRNA (25) . The level of apoE mRNA in differentiated adipocytes is increased further by raising the content of intracellular free cholesterol (25) , a process that can be stimulated in adipocytes by the induction of LDL receptor-related protein by insulin (26) . Thus, the regulation of apoE production in both adipocytes and macrophages has intriguing similarities; the gene is not expressed in cellular precursors but is induced upon differentiation into mature cells and is further induced in each cell type by intracellular cholesterol and by a synthetic glucocorticoid. Consequently, it is likely these processes are controlled by common regulatory elements that are active in both cell types.
The human apoE gene is located on chromosome 19 at the 5Ј end of a 44-kilobase (kb) gene cluster that includes the apoC-I, apoC-IV, and apoC-II genes and the apoC-IЈ pseudogene (27, 28) . The apoE gene is expressed in many tissues throughout the body (29) , although 90% of the apoE circulating in plasma is synthesized by the liver (30) . Cell-specific distal enhancers control the expression of the apoE gene cluster in all tissues (31, 32) . The promoters lack the ability to direct gene transcription in vivo in any cell in the absence of the distal enhancers (33) . The locations of two enhancers, hepatic control regions (HCR) 1 and 2, have been reported; HCR.1 is found 15 kb 3Ј of the apoE gene, and HCR.2 is located 11 kb farther downstream (34, 35) . The two hepatocyte-specific enhancers have an 87% sequence identity, and they apparently arose as a result of the recent evolutionary gene duplication that yielded the apoC-I and apoC-IЈ genes (28) . We report here on the localization of two macrophage/adipocyte enhancers that are nearly identical in sequence, constituting the second example of the regulatory impact of gene duplication on the control of gene expression in the apoE gene cluster.
MATERIALS AND METHODS

Constructs and Transgenic
Mice-The constructs employed for these studies are illustrated in Fig. 1, A and B. The preparations of the 70-kb 198.KK cloned genomic fragment and the 10-kb HEG1, HESS1, LE1, LE2, and LE6 subfragments have been described (27, 34) . The CLE1 clone (36) consists of the intact human apoE gene, 30 kb of 5Ј-flanking sequence, and 2.75 kb of 3Ј-flanking sequence. The 3Ј terminus of the genomic insert was determined by nucleotide sequencing. The LE7, LE8, and LE9 DNA subfragments containing 672-, 597-, and 603-bp sequences, respectively, were generated by polymerase chain reaction (PCR) from the LE1 DNA subfragment. Oligonucleotide sequences for PCR were as follows: 1) LE7 5Ј end primer, 5ЈCCCAAGCTTCAACAT-GCGTTAGGAGGGACAT3Ј; 2) LE7 3Ј end primer, 5ЈGGACTAGTCCC-TATCAGATGGGCGTCTTTA3Ј; 3) LE8 5Ј end primer, 5ЈCCCAAGCT-TCACTGAGCCCTACTGGATGTTC3Ј; 4) LE8 3Ј end primer, 5ЈGGAC-TAGTCCTTCAGCTGCAAAGCTCTGAG3Ј; 5) LE9 5Ј end primer, 5ЈC-CCAAGCTTAGTGTCCAGCTAAGGCGAC3Ј; 6) LE9 3Ј end primer, 5ЈGGACTAGTGCCCGCAGGACCTTTATCAG3Ј. The resulting PCR products were digested with HindIII and SpeI and ligated to purified HEG1 to make transgene constructs (HEG.LE1 in Fig. 1A ). Construct DNA was purified by standard methods (35) .
All transgenic animals for these studies were generated in the inbred FVB/N mouse strain with constructs of the human apoE gene cluster (Fig. 1, A and B) as described previously (27) . Construct DNA was microinjected into zygotes at a concentration of 2 ng/l in 5 mM TrisHCl, pH 7.4, 0.2 mM EDTA. Transgenic founders and hemizygous offspring were identified by PCR analysis of tail tip DNA, and genomic DNA was analyzed further to confirm the presence of the LE7, LE8, and LE9 sequences in their respective transgenes. Two to four independent transgenic lines were analyzed for each construct, and cell or tissue samples from male and female mice were examined independently.
Macrophage Isolation and Culture-Mouse peritoneal macrophages were collected 4 days after an intraperitoneal injection of 1.5 ml of sterile 4% thioglycollate broth (Difco). All subsequent procedures were carried out under sterile conditions. The cells were collected by intraperitoneal lavage with sterile Dulbecco's phosphate-buffered saline (PBS). The lavage fluid from three mice was pooled and centrifuged for 10 min at 800 ϫ g. Pelleted cells were resuspended in Dulbecco's minimal essential medium (DMEM) and then centrifuged again. After a second resuspension in DMEM, the cells were counted, and 3-10 ϫ 10 6 cells were plated in 35-mm culture dishes. Nonadherent cells were removed after 3 h by two washes with DMEM, and the remaining macrophages were incubated overnight in DMEM supplemented with 20% fetal bovine serum.
Preparation and Analysis of Total RNA-Macrophage RNA was extracted by using Trizol Reagent (Life Technologies, Inc.) following the manufacturer's protocol. RNA hybridization probes for human apoE mRNA were transcribed as described (34) by using bacteriophage T3 RNA polymerase in the presence of [␣-
32 P]UTP (10 mCi/ml, Amersham Pharmacia Biotech) from cDNA fragments that had been cloned in Bluescribe vectors (Stratagene, La Jolla, CA). A mouse actin mRNA probe (m-actin 79) that was transcribed by using SP6 RNA polymerase was used to estimate the levels of RNA present in each sample. Human apoE and mouse actin protected 192 and 80 nucleotides, respectively, of their respective probes. RNase protection analysis was performed as described (37) with 5 g of total cellular RNA per sample. Protected fragments were resolved by electrophoresis in 6% polyacrylamide gels containing 7 M urea and detected by autoradiography of the dried gels.
In Situ Hybridization-Adipose tissues from retroperitoneal, inguinal, and reproductive sites from control and transgenic mice were fixed in 4% paraformaldehyde for 24 -36 h and embedded in paraffin. Sections (7 m) were cut with a rotary microtome, mounted on superfrost plus slides (Fisher), and stored at 4°C until used. Before hybridization, slides were warmed to room temperature and baked at 55°C for 30 min. Paraffin was removed from the slides by two successive 10-min immersions in xylene. Tissue sections were hydrated in a progression of 3-min washes in ethanol (100, 90, 70, 50, and 30%) and by three successive 5-min immersions in 1ϫ PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 ⅐7H 2 O, 1.4 mM KH 2 PO 4 , pH 7.3). The sections were incubated with 20 g/ml proteinase K (Roche Molecular Biochemicals) in 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl for 15 min at room temperature. Proteolytic activity was stopped by immersion for 10 min in 0.2% glycine in 1ϫ PBS. Tissues were successively rinsed in 1ϫ PBS for 5 min, fixed in 4% paraformaldehyde in 1ϫ PBS for 5 min, rinsed in 1ϫ PBS for 5 min, and acetylated with 0.25% acetic anhydride in 0.1 mM triethanolamine buffer at pH 8.0 for 10 min. After a final 5-min rinse in 1ϫ PBS, tissue sections were dehydrated in a series of 3-min washes in ethanol (30, 50, 80, 95, and 100% ). An RNA probe complementary to nucleotides 20 -411 of human apoE mRNA was labeled with [␣- 33 P]UTP to a specific activity of at least 2 ϫ 10 4 Ci/mmol by using an RNA transcription kit (Stratagene). Labeled probes were purified through Micro Bio-Spin 30 chromatography columns (Bio-Rad).
Tissue sections were incubated for 14 -18 h in a humidified chamber at 42°C with probes diluted to 2.0 ϫ 10 6 cpm per slide in a buffer containing 50% formamide, 0.3 M NaCl, 20 mM Tris, pH 8.0, 5 mM EDTA, 1ϫ Denhardt's solution (0.2% polyvinylpyrrolidone, 0.02% Ficoll, 0.02% bovine serum albumin), 10% dextran sulfate, 250 g/ml sperm DNA, and 0.1 mg/ml tRNA. The sections were washed twice at room temperature in 2ϫ standard saline citrate solution (SSC), 1.0 mM EDTA for 10 min, and immersed in 20 g/ml RNase A (Sigma) in 500 mM NaCl, 10 mM Tris, pH 8.0, and 10 units/ml of T1 RNase (Roche Molecular Biochemicals) for 1 h at 37°C. Tissue sections were washed at 55°C in six changes of 0.1ϫ SSC with 1.0 mM EDTA for 4 h, rinsed twice for 10 min each in 0.5ϫ SSC, dehydrated, and exposed at Ϫ20°C to ␤-max film (Amersham Pharmacia Biotech) for 4 days. Slides were dipped in NTB2 nuclear track emulsion (Eastman Kodak Co.), incubated at 4°C for 5 days, and developed with D19 developer (Kodak). Sections were stained for 2 min with hematoxylin (Fisher), washed in Scott's Tap Water Substitute (Fisher) for 3 min, placed in 80% ethanol for 1 min, and then restained with eosin (Fisher) for 3 min. After dehydration in a graded series of ethanol (80, 95, and 100%), the sections were rinsed in xylene three times and overlaid with coverslips.
Nucleotide Sequence Analysis-Nucleotide sequences of intergenic regions in the human apoE gene cluster were determined by standard methods (27) . ApoE gene cluster sequences are also available in the GenBank TM data base (accession number AF050154). The nucleotide sequences were analyzed by Pustell DNA matrix and ClustalW alignment algorithms contained in the MacVector software suite (Oxford Molecular, Madison WI), and by sequence comparison algorithms in the Vector NTI (Informax, North Bethesda, MD) suite of programs. Additional analysis of nucleotide homologies was made by searching the GenBank TM and TRANSFAC (38) data bases.
RESULTS AND DISCUSSION
To determine the location of regulatory sequences that direct apoE gene expression in macrophages, peritoneal macrophages were isolated from transgenic mice that had been generated with the p198.KK, CLE1, and HEG1 genomic fragments (Fig.  1A) . Total RNA was extracted and analyzed by RNase protection analysis. Macrophages from p198.KK transgenic mice contained human apoE mRNA, whereas cells from CLE1 and HEG1 did not react with the human antisense RNA probe (Fig.  2) . No RNA samples from any tissues of these mice hybridized to the apoE sense RNA probe (data not shown). These initial results suggested that no macrophage-specific regulatory activity was located in the proximal promoter or within 30 kb upstream of the apoE gene and that macrophage enhancer activity was located more than 1.7 kb downstream of the gene.
Previous studies indicated that the HCR.1 domain had unique enhancer properties with a potential nuclear matrix attachment sequence and nucleosome organizing capability (39) . 2 Therefore, we examined transgenic mice generated with constructs that covered this region of the apoE gene cluster to determine if macrophage expression activity might be located near HCR.1 (Fig. 1, A and B) . Human apoE mRNA was detected in macrophage RNA from transgenic mice generated with HEG.LE1 and HEG.LE2 but not with HEG.LE6 (Fig. 2) . To confirm the site of macrophage enhancer activity, additional constructs were generated that had the LE7, LE8, or LE9 portion of the LE1 domain. The HEG.LE8 construct expressed the apoE gene in macrophages, and only constructs that contained the LE8 sequence yielded human apoE mRNA in these cells (Fig. 2) .
A previous report (40) indicated that activation of apoE gene expression in vitro during macrophage differentiation of cultured transformed THP-1 cells is associated with a regulatory element in the proximal promoter of the apoE gene that binds the transcription factor activator protein-1. This element was mapped to ϳ600 nucleotides upstream of the transcription start site of the apoE gene, which places the regulatory element within a member of the Alu family of repeated sequences (41) . Although this regulatory element is present in the HEG1 genomic fragment, our results show that HEG1 is not expressed in macrophages in vivo without the presence of the downstream multienhancer domain (Fig. 2) .
The similarities in the control of apoE production reported for both macrophages and adipocytes suggested that the same regulatory domain might contain enhancer activity for apoE gene expression in both cell types. Therefore, adipose tissue was collected from adipose fat pads at three different sites from transgenic mice generated with various constructs (Fig. 1, A  and B) and was examined by in situ hybridization. ApoE mRNA was detected in adipocytes from HEG.LE2 but not HEG.LE6 transgenic mice (Fig. 3, A and B) . No difference in apoE expression was observed in adipose tissue excised from any of the three sites examined (data not shown). Human apoE mRNA was also found in adipose tissue from p198. KK (54) have demonstrated that shorter segments of HCR.1 have liver enhancer properties. The lengths of fragments (shaded bars) that were prepared and ligated to the 3Ј end of HEG1 (as illustrated for LE1 in Fig. 1A ) for generating transgenic mice are given in bp. The ME.2 domain is indicated; its enhancer activity is given by all fragments that contain this sequence.
FIG. 2.
Expression of apoE mRNA in control and transgenic mouse macrophages. Total RNA from isolated peritoneal macrophages was examined by RNase protection analysis using antisense probes for human apoE (upper panel) and actin (lower panel). Transgenic lines examined are indicated. Control macrophage RNA was derived from nontransgenic mice. All of the transgenic lines are expressed in kidney proximal tubule epithelia as a consequence of endogenous enhancer activity in the 5Ј-flanking region of the human apoE gene (34); therefore, kidney RNA was examined to verify the activity of the human apoE probe. A typical result with kidney and liver RNA from HEG1 transgenic mice is shown. Only 198.KK, HEG.LE1, HEG.LE2, and HEG.LE6 are expressed in the liver (data not shown).
by RNase protection (Fig. 4) . These data confirmed that the LE8 portion, but not the LE7 or LE9 portion, of the LE1 domain directed transgene expression to adipose tissue. Thus, both adipose enhancer activity and macrophage enhancer activity co-localized to the same LE8 intergenic region.
The sequence of the LE8 region was compared with the nucleotide sequence of the human apoE gene cluster to determine if there were homologous sequences present elsewhere within this genomic domain. A 620-nucleotide region of homology was identified in the apoE/C-I intergenic region, located 3.3 kb downstream of the apoE gene. A comparison of the entire LE8 sequence and its upstream homologous sequence is shown in Fig. 5 . The two regions are 95% identical in sequence, having a random distribution of nucleotide differences. A single nucleotide deletion located near the 5Ј terminus of LE8 accounts for their difference in length. This sequence identity is greater than that of HCR.1 and HCR.2 (28) , suggesting that enhancer function was likely to be preserved in both domains. Analysis of macrophage RNA from HESS1 (Fig. 1A) transgenic mice supported the likelihood that the apoE/C-I intergenic element had full enhancer activity (Fig. 2) . Similarly, adipose tissue from HESS1 transgenic mice was positive for apoE mRNA as determined by in situ hybridization (data not shown). We termed the upstream sequence multienhancer 1 (ME.1) and the downstream sequence multienhancer 2 (ME.2).
Our identification of the multienhancer domains depended on the expression of human genomic fragments in transgenic mice. To minimize the possibility that our results might reflect potential position effects from neighboring sequences at the sites of transgene integration in the host mouse genome, we examined at least two independent founder lines for each construct. In addition, transgenic lines were generated with several different constructs containing the multienhancer domains (Fig. 1, A and B) . The same pattern of expression was observed in each case, making it unlikely that artifactual position effects contributed to the cell specificity of transgene expression.
To understand the regulatory activity of the ME.1 and ME.2 domains, we examined their nucleotide sequences for transcription factor binding motifs. Several high affinity binding motifs for the glucocorticoid receptor (GR) and members of the CAAT element binding protein (C/EBP) transcription factor family were found throughout both multienhancer domains, as illustrated for ME.1 in Fig. 6 . Although the transcriptional activities of these motifs remain to be evaluated by direct functional tests, their presence in ME.1 and ME.2 is consistent with the roles of GR and C/EBP factors in macrophage and adipocyte function. For example, C/EBP␣ and C/EBP␤ play obligatory roles in adipocyte differentiation, a process that is further modulated by glucocorticoids (42, 43) . In addition, C/EBP␣ is required for full activity of the promoters of several genes that are expressed in mature macrophages (44 -46) . Furthermore, both C/EBP␣ and C/EBP␤ appear to play critical roles in macrophage maturation (47) .
The possibility that widely employed transcription factors like GR and C/EBP mediate ME.1 and ME.2 function suggests that interactions with specific cofactors are likely to be critical to achieving tissue-specific enhancer action. This mechanism has been suggested to account for the cell-specific activity of the peroxisome proliferator-activated receptors (PPARs) (48) , another transcription family that is important for gene expression in macrophages, adipocytes, and other tissues (49) . Cofactor interactions and protein modifications, including phosphorylation, appear to be important in mediating PPAR binding to low affinity binding sites in regulatory domains of responsive genes (48) . Consequently, our finding of high affinity binding motifs for GR and C/EBP, and the apparent lack of high affinity binding sites for PPAR in ME.1 and ME.2 (Fig. 7, legend) , will require direct functional tests to evaluate their role in enhancer activity for the apoE gene. Clarification of these mechanisms is beyond the scope of this report, and we will test them in future studies.
The finding of one copy of a duplicate enhancer element in the 5Ј-flanking region of the apoC-IЈ gene (ME.2) and a second copy in the apoE/C-I intergenic region (ME.1) was unexpected. Our previous sequence analysis indicated that homology between the two apoC-I genes ended 259 nucleotides upstream of the apoC-I gene. However, Pustell DNA matrix analysis of the 
FIG. 4.
Localization of an adipose tissue enhancer. Total RNA isolated from tissues of transgenic mice was analyzed by RNase protection as in Fig. 2 with antisense probes for apoE mRNA (A-C) and actin (D-F). Only the HEG.LE8 construct is expressed at high levels in adipose tissue. The expression patterns of each construct in the three other tissues shown here serve as controls for this analysis. The HEG1 parent construct is normally expressed at high levels in the kidney, and this activity is retained in all three constructs as expected. A distinct enhancer domain (HCR.1) is located within the LE7 fragment and directs expression of the transgene at high levels in the liver, as previously reported (34) . Little if any expression of HEG1 is detected in testis (34), a pattern consistent with the expression of the transgenes analyzed here. apoE gene cluster sequence compared with itself revealed an additional region of internal homology located 467 nucleotides further upstream of the apoC-I promoter. This upstream sequence was strikingly similar to sequences within the LE1 fragment where the apoC-IЈ 5Ј-flanking region is located (Fig.  7) . The 5Ј region of sequence duplication extends 12 nucleotides into the adjacent Alu repeated sequence member, at which point nucleotide similarities diverge sharply (data not shown). Within the duplicated region, sequence identities are remarkably high, consistent with a conserved regulatory function for these regions.
A comparison of the ec7 and cc13 Alu sequences (locations indicated in Fig. 7 ) reveals a 94% sequence identity (data not shown). This degree of sequence conservation is significantly greater than the 87% average identity found for ϳ500 members of a major Alu subfamily (50) and the 86% identity for Alu sequences at large in the human genome (51) . The relatively high conservation of the ec7 and cc13 Alu sequences is consistent with the recent evolutionary duplication of the apoC-I genes (52) . Finding that the sequence identity between these particular Alu family members is comparable to that of the adjacent enhancer domains suggests that they may have a functional contribution to the apoE gene cluster, a possibility that remains to be determined.
Our previous studies indicated that a 10-kb segment of the human apoE gene cluster had undergone a duplication event that resulted in the appearance of two copies of the apoC-I gene (27) . We determined by nucleotide sequence analysis that the distal downstream end of the duplicated segment was located at the 3Ј end of HCR.2 (28) . In the current study, both matrix analysis and direct sequence comparisons show that the upstream 5Ј end of the duplicated genomic segment is at the 5Ј end of the ME.1 domain and extending 12 nucleotides into the adjacent Alu sequence (Fig. 7) . Thus, the upstream duplicated segment containing the functional apoC-I gene is 12 kb in length, and the downstream duplicated segment containing the inactive apoC-IЈ pseudogene is 11 kb in length.
The studies presented here show that the gene recombina- FIG. 5 . Nucleotide sequences of macrophage enhancer regions. The nucleotide sequences of the ME.1 and ME.2 enhancer domains are shown. Nucleotide differences are indicated by dark boxes, and a single nucleotide deletion is indicated by a dash.
FIG. 6. Transcription factor binding motifs in the multienhancer domain.
The relative locations of binding motifs with 80% or greater identity to high affinity core-binding sequences for the GR, C/EBP␣, and C/EBP␤ are shown. The analysis of ME.1 via the binding motifs of the TRANSFAC data base (38) is illustrated here. The ME.2 sequence yielded the same result (data not shown). Further analysis for high affinity binding sites for the PPAR␣ and PPAR␥ families was performed with the MacVector suite and the VectorNTI suite using binding motifs summarized in C (48) . No high affinity binding motifs for either PPAR transcription factor family were identified.
FIG. 7.
Macrophage enhancer domains of the apoE gene cluster. The conserved sequences of the 5Ј-flanking regions of the apoC-I and apoC-IЈ genes, as well as the 5Ј portions of these genes, are illustrated as in Fig. 1 . Lengths of 5Ј-flanking regions are given in bp, and nucleotide sequence identities of distinct domains in these regions are indicated.
tion events that resulted in the modern day human apoE gene cluster yielded duplicated enhancers, HCR.1 and HCR.2, for hepatocyte expression and duplicated enhancers, ME.1 and ME.2, for macrophage and adipocyte expression. The enhancer HCR.2 is located at the extreme 3Ј end of the recombinant portion of the cluster, and ME.1 is located at the extreme 5Ј end of the recombinant region (Fig. 1) . Additional studies are underway to determine if distinct regulatory elements within ME.1 and ME.2 can be distinguished for the control of gene expression in macrophages and adipocytes.
